Tremelimumab Clinical Trials
31 recruitingDrug
Phase 220Phase 37Phase 16Early Phase 11
Showing 1–20 of 31 trials
Recruiting
Phase 3
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Advanced Hepatocellular Carcinoma
NRG Oncology226 enrolled107 locationsNCT07166406
Recruiting
Phase 2
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaInvasive Breast Carcinoma
National Cancer Institute (NCI)70 enrolled30 locationsNCT03606967
Recruiting
Phase 2
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Georgetown University18 enrolled4 locationsNCT04499053
Recruiting
Early Phase 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Phase 2
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Hepatocellular Carcinoma Non-resectableHCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest55 enrolled12 locationsNCT04522544
Recruiting
Phase 2
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+1 more
Emory University39 enrolled4 locationsNCT07174570
Recruiting
Phase 1Phase 2
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Gastric CancerHepatocellular CarcinomaEsophageal Adenocarcinoma
Anwaar Saeed117 enrolled2 locationsNCT03539822
Recruiting
Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca1,220 enrolled204 locationsNCT06921785
Recruiting
Phase 2
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
Hepatocellular CarcinomaCirrhosis, Liver
The University of Texas Health Science Center at San Antonio32 enrolled1 locationNCT06526104
Recruiting
Phase 2
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca114 enrolled24 locationsNCT07081633
Recruiting
Phase 2
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8+4 more
Mary Feng, MD21 enrolled1 locationNCT04430452
Recruiting
Phase 1
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins25 enrolled1 locationNCT06564623
Recruiting
Phase 2
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Hepatocellular Carcinoma
Anwaar Saeed40 enrolled3 locationsNCT06698250
Recruiting
Phase 3
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Carcinoma, Non-Small Cell Lung
AstraZeneca280 enrolled105 locationsNCT06008093
Recruiting
Phase 1
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma+2 more
Mayo Clinic16 enrolled1 locationNCT06058663
Recruiting
Phase 2
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
HCC - Hepatocellular CarcinomaDurvalumabTremelimumab+1 more
Chang Gung Memorial Hospital45 enrolled1 locationNCT06999694
Recruiting
Phase 1
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Hepatocellular CarcinomaHepatocellular CancerResectable Hepatocellular Carcinoma
Jiping Wang, MD, PhD20 enrolled3 locationsNCT05701488
Recruiting
Phase 2Phase 3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
AbbVie660 enrolled37 locationsNCT06109272
Recruiting
Phase 2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Pancreatic CancerBiliary Tract CancerCholangiocarcinoma+1 more
AHS Cancer Control Alberta62 enrolled1 locationNCT05451043
Recruiting
Phase 2
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Cancer
Canadian Cancer Trials Group60 enrolled12 locationsNCT03847649